n°208

October 2019

Issue Contents
Editorial

Free  Between hope and reality

p.227

Marketing Authorisations

Axicabtagene ciloleucel (Yescarta°) in certain types of lymphoma when other treatment options have been exhausted

p.229-231
A CAR T-cell therapy that increases the chances of survival but frequently provokes serious adverse effects

Inset. CAR T-cell therapies

p.230-231

Inset. Tisagenlecleucel (Kymriah°) in relapsed or refractory diffuse large B-cell lymphoma

p.231

Tisagenlecleucel (Kymriah°) in acute lymphoblastic leukaemia in children and young adults

p.232-233
Increases the chances of survival, but with major adverse effects

INN Common stem: -ciclib

p.233

Evolocumab (Repatha°) in secondary prevention of cardiovascular disease

p.234-237
No reduction in either all-cause or cardiovascular mortality

Inset. Alirocumab in secondary prevention of cardiovascular disease: conflicting mortality data

p.235

Adverse Effects

Drug-induced cytokine release syndrome

p.238-240

Nonsteroidal anti-inflammatory drugs (NSAIDs) at the start of pregnancy: early miscarriage

p.240-241

Pentoxyverine: antimuscarinic adverse effects and cardiac disorders

p.241-242

Reviews

Acute low back pain without radiculopathy

p.243-246
Paracetamol and ibuprofen have modest efficacy, at best

Outlook

Free  Trials funded by drug companies: publication or publicity?

p.247

Free  Independence of French medical schools: clear shortcomings

p.248

Paracetamol: patients are not sufficiently aware of the harms

p.249-250

Queries and Comments. What cardiovascular adverse effects occur with vasoconstrictors used for colds?

p.250-251

Masthead

Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe